Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastrointest Surg. Jun 27, 2016; 8(6): 427-435
Published online Jun 27, 2016. doi: 10.4240/wjgs.v8.i6.427
Table 1 Patients’ demographic data, todani bile duct cyst subtypes and imaging studies
Patient with previous CEPatient without previous CETotalP value
Patients16227243-
Median age (yr) at the time of BDC resection47.8 (26-60)29.2 (0-81)30.8 (0-81)0.0074
Sex ratio F/M73.733.80.5359
Adults/children16/0148/79164/790.0041
ASA score1
1 or 215 (93.75%)217 (95.6%)232 (95.0%)0.5350
≥ 31 (6.3%)10 (4.4%)11 (4.5%)
Types of imaging studies
None (incidental detection)1 (6.3%)2 (0.9%)3 (1.2%)0.1855
Percutaneous ultrasound8 (50.0%)188 (82.8%)196 (80.7%)0.0042
Computed tomography7 (43.8%)119 (52.4%)126 (51.9%)0.5022
MR- cholangiography9 (56.3%)138 (60.8%)147 (60.5%)0.7194
ERCP7 (43.8%)40 (17.6%)47 (19.3%)0.0186
Endoscopic ultrasound8 (50.0%)36 (15.9%)44 (18.1%)0.0026
Percutaneous cholangiography017 (7.5%)17 (7.0%)0.6115
Intravenous cholangiography2 (12.5%)13 (5.7%)15 (6.2%)0.2583
Intraoperative cholangiography06 (2.6%)6 (2.5%)1.0000
Todani bile duct cyst types
Type I16221237
Type IVB0661.0000
MBC adequately analyzed12 (75%)196 (86%)208 (85.5%)
Cyst involvement of MBC5/12 (41.6%)47/196 (24.0%)52 (21.4%)0.3173
MBC-133942
MBC-228100.2420
Presence of PBM adequately explored10180190
Presence of anomalous PBM8 (80.0%)141 (78.3%)149 (78.4%)1.0000
Table 2 Patients’ clinical presentation
Patients with previous CE n = 16Patients without previous CE n = 227Total n = 243P value
Median delay between symptoms and diagnosis (mo) (range)2 (0-486)2 (0-360)2 (0-486)0.8848
Type of symptoms and signs
Asymptomatic2 (12.5%)31 (13.7%)33 (13.6%)1.0000
Isolated pain2 (12.5%)104 (45.8%)106 (43.6%)0.0094
Cholangitis12 (75%)52 (22.9%)64 (26.3%)< 0.0001
Pancreatitis2 (12.5%)49 (21.6%)51 (21.0%)0.5344
Abdominal mass2 (12.5%)22 (9.7%)24 (9.9%)0.6631
Jaundice16 (37.5%)59 (26.0%)65 (27.2%)0.3843
Pruritus1 (6.2%)2 (0.9%)3 (1.2%)0.1855
Weight loss2 (12.5%)6 (2.6%)8 (3.2%)0.0903
Complicated presentation12 (75%)92 (40.5%)104 (42.8%)0.0071
Number of patients with > 2 symptoms9 (56.25%)92 (40.5%)102 (42.0%)0.2942
Table 3 Coexistent hepato-biliary and pancreatic diseases
Patients with previous CE n = 16Patients without previous CE n = 227Total n = 243P value
Biliary disease9 (56.2%)52 (22.9%)61 (25.1%)0.0059
Common biliary atresia01 (0.4%)1 (0.4%)1.0000
Stones4 (25%)37 (16.3%)41 (16.9%)0.3216
Gallbladder016 (7.0%)16 (6.6%)-
Cyst3 (18.8%)9 (4.0%)12 (4.9%)-
Common bile duct1 (6.3%)22 (9.7%)23 (9.5%)-
Intra hepatic duct04 (1.8%)4 (1.6%)-
Synchronous cancer5 (31.3%)14 (6.2%)19 (7.8%)0.0043
Table 4 Preoperative treatment and types of surgery
Patients with previous CE n = 16Patients without previous CE n = 227Total n = 243P value
Preoperative biliary drainage2 (12.5%)14 (6.2%)16 (6.6%)0.2842
Types of surgical procedures
Absence of resection1 (6.3%)5 (2.2%)6 (2.5%)0.3384
Elective surgery14 (87.5%)214 (94.3%)228 (93.8%)0.2583
Emergency surgery1 (6.2%)9 (4.0%)10 (4.1%)0.5007
Complete cyst excision13 (81.2%)199 (87.6%)212 (87.2%)0.6631
Incomplete cyst excision2 (12.5%)23 (10.1%)25 (10.3%)
Superior excision1 (6.3%)13 (5.7%)14 (5.8%)
Inferior excision1 (6.3%)9 (4.0%)10 (4.1%)-
Unknown01 (0.4%)1 (0.4%)
Associated procedures
Hepatectomy2 (12.5%)4 (1.8%)6 (2.5%)0.0523
Pancreaticoduodenectomy4 (25.0%)4 (1.8%)8 (3.3%)0.0008
Stone extraction2 (12.5%)10 (4.4%)12 (4.9%)0.2072
Synchronous cancer excision5 (31.3%)13 (5.7%)118 (7.8%)0.0043
Biliary reconstruction
Hepatico-jejunostomy13 (81.2%)208 (91.6%)221 (90.9%)0.1658
Hepatico-duodenostomy2 (12.5%)7 (3.1%)9 (3.7%)0.1116
Choledoco-duodenostomy01 (0.4%)1 (0.4%)1.0000
MBC anastomosis8/14 (57.1%)96/180 (53.3%)104/194 (53.6%)0.7831
Table 5 Early postoperative and long term outcome of patients
Patients with previous CE n = 16Patients without previous CE n = 227Total n = 243P value
Median postoperative hospital stay (d) (range)16 (9-110)10 (2-150)10 (2-150)0.0014
Mortality rate0 (0.0%)1 (0.4%)1 (0.4%)1.0000
Overall complications12 (75.0%)75 (33%)87 (35.8%)0.0018
Grade I-II5 (31.3%)47 (20.9%)52 (21.4%)0.3454
Grade III-IV7 (43.8%)28 (12.3%)35 (15.4%)0.0031
Surgical complications7 (43.8%)45 (19.8%)52 (21.4%)0.0509
Biliary0 (0.0%)20 (8.8%)20 (8.2%)0.3750
Mixed pancreatic and biliary fistula1 (6.3%)5 (2.2%)6 (2.5%)0.3384
Pancreatic1 (6.3%)17 (7.5%)18 (7.4%)1.0000
Bleeding5 (31.3%)3 (1.3%)8 (3.3%)< 0.0001
Reoperation rate6 (37.5%)20 (8.8%)26 (10.7%)0.0032
Long-term outcome of patients
Patients with previous CE n = 13Patients without previous CE n = 185n = 198
Median follow-up (mo) (range)59 (12-175)36 (4-372 )37.5 (4-372)0.2482
Mayo clinic score
Excellent5 (38.5%)138 (74.6%)143 (72.2%)
Good2 (15.4%)18 (9.7%)20 (10.1%)0.0099
Fair05 (2.7%)5 (2.5%)
Poor6 (46.2%)24 (13.0%)30 (15.1%)
Mayo clinic score
Excellent + good7 (53.8%)156 (84.3%)163 (82.3%)0.0136
Fair + poor6 (46.2%)29 (15.7%)35 (17.7%)
Table 6 Predictive factors of poor and fair long-term outcome according to Mayo clinic score in 198 patients with a follow-up > 3 mo, including patients suffering from synchronous cancer
CovariateUnivariate
Multivariate
OR95%CIP valueOR95%CIP value
Adult patient vs child3.5871.322-9.7350.0084---
Previous cyst-enterostomy; Yes vs No4.6111.445-14.7120.01363.1650.829-12.0770.0918
Synchronous cancer; Yes vs No18.4624.687-72.71< 0.000116.6123.999-69.0130.0001
Post-operative complications; Yes vs No2.3971.143-5.0280.0186---
Postoperative biliary complications; Yes vs No4.3561.669-11.3670.00384.5971.635-12.9250.0038